Evaluation of discharge prescriptions for secondary prevention in patients with acute coronary syndromes in Iraq

Citation

Nassr OA, Forsyth P & Johnson CF (2019) Evaluation of discharge prescriptions for secondary prevention in patients with acute coronary syndromes in Iraq. Pharmacy Practice, 17 (1), Art. No.: 1372. https://doi.org/10.18549/PharmPract.2019.1.1372

Abstract
Background: Optimal prescribing of secondary prevention medications after acute coronary syndrome (ACS) events has been shown to reduce morbidity and mortality. However, it is unknown whether these medications are optimally prescribed at discharge from acute care in Iraq. Objective: To evaluate whether patients with ACS received optimal secondary prevention medications: antiplatelets, statins, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEI/ARBs), and beta-blockers at discharge from a cardiology unit, and to assess whether statins, ACEI/ARBs and beta-blockers were prescribed at target doses based on the American Heart Association/American College of Cardiology (AHA/ACC) guidelines. Methods: Observational retrospective cross-sectional study of patients with ACS admitted to a hospital in Baghdad and survived to discharge between May 2016 and January 2017. Patient-level data and secondary prevention medications at discharge were extracted from routine medical records. Optimal dosing was defined as ≥75%, moderate dosing as 50–74%, and low dosing as

Keywords
Acute Coronary Syndrome; Professional Practice; Guideline Adherence; Drug Utilization; Angiotensin-Converting Enzyme Inhibitors; Angiotensin Receptor Antagonists; Clinical Audit; Iraq

Journal
Pharmacy Practice: Volume 17, Issue 1

• Published version